Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Leukemia, not otherwise specified | Leukemia, other | Pediatrics
What is the purpose of this trial?
This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.
- Trial withChildren's Oncology Group (COG)
- Start Date05/27/2022
- End Date05/11/2022
- Last Updated07/12/2022
- Study HIC#2000027013